Last reviewed · How we verify
rLP2086
rLP2086 is a recombinant lipoprotein that mimics a naturally occurring lipoprotein to activate the immune system against meningococcal bacteria.
rLP2086 is a recombinant lipoprotein that mimics a naturally occurring lipoprotein to activate the immune system against meningococcal bacteria. Used for Prevention of invasive meningococcal disease (serogroups A, B, C, W, Y).
At a glance
| Generic name | rLP2086 |
|---|---|
| Sponsor | Pfizer |
| Drug class | Recombinant protein vaccine |
| Target | Neisseria meningitidis lipoproteins |
| Modality | Biologic |
| Therapeutic area | Immunology / Infectious Disease |
| Phase | Phase 3 |
Mechanism of action
rLP2086 is a recombinant lipidated protein designed to present meningococcal epitopes in a manner that stimulates both innate and adaptive immune responses. It targets conserved regions of Neisseria meningitidis lipoproteins to provide broad protection against multiple meningococcal serogroups. The vaccine candidate aims to induce bactericidal antibodies and cellular immunity against invasive meningococcal disease.
Approved indications
- Prevention of invasive meningococcal disease (serogroups A, B, C, W, Y)
Common side effects
- Injection site pain
- Injection site erythema
- Fatigue
- Myalgia
- Headache
Key clinical trials
- A Clinical Trial to Assess the Safety, Tolerability and Immunogenicity of MenABCWY in Healthy Infants (PHASE2)
- A Trial to Describe the Immunogenicity and Safety of 2 Doses of Bivalent rLP2086 (Trumenba) and a Pentavalent Meningococcal Vaccine in Healthy Subjects >=10 to <26 Years of Age. (PHASE3)
- A Trial To Assess The Safety, Tolerability, And Immunogenicity Of Rlp2086 Vaccine When Administered In Either 2- Or 3-Dose Regimens In Healthy Subjects Aged ≥11 To <19 Years (PHASE2)
- A Trial to Assess the Safety, Tolerability and Immunogenicity of Repevax and rLP2086 Vaccine When Given Together in Healthy Subjects Aged >=11 to <19 Years. (PHASE2)
- Immunogenicity, Safety and Tolerability of a Neisseria Meningitidis Serogroup B Bivalent Recominant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Toddlers. (PHASE2)
- A Study to Describe the Immunogenicity, Safety, and Tolerability of Neisseria Meningitidis Serogroup B Bivalent Recombinant Lipoprotein 2086 Vaccine (Bivalent rLP2086) in Healthy Subjects Aged ≥24 Months to <10 Years (PHASE2)
- Duration of hSBA Response After a Primary Series of Bivalent rLP2086 Followed by a Booster Dose (PHASE3)
- A Clinical Trial to Study the Safety, Tolerance and Immunogenic Response to MCV4, Tdap and Bivalent rLP2086 Vaccine When Given at the Same Time to Children Between the Ages of 10 Through 12 Years of Age (PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- rLP2086 CI brief — competitive landscape report
- rLP2086 updates RSS · CI watch RSS
- Pfizer portfolio CI